Meet the Proteona team at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, USA
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona will be at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco from the 13th to the 16th January, 2020.
The annual event is the largest symposium for healthcare investment, attracting industry players, startups, and investors. We are excited to be there to discuss the impact of single cell multi-omics on the future of precision medicine. See you there!
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a new biomedical company based in Singapore, Germany, and the US that is pioneering the use of DNA barcoded antibodies to provide both proteomic and genomic information from the same single cells. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research’s (A*STAR). The platform is a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles.